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Objective: Intra-lesional bony overgrowth (BO) identiﬁed during or following cartilage repair treatment
is being frequently described through subjective reports focusing primarily on incidence. Our objective
was to quantify the exact volume of intra-lesional BO at 12 months post-cartilage repair treatment, to
determine if a correlation exists between the extent of BO and clinical outcomes, and to visualize and
characterize the BO.
Design: MRI scans were systematically obtained during a randomized clinical trial for cartilage repair
(Stanish et al., 2013) that compared two microfracture-based treatments in 78 patients. Semi-automated
morphological segmentation of pre-treatment, 1 and 12 months post-treatment scans utilizing a pro-
grammed anatomical atlas for all knee bone and cartilage structures permitted three-dimensional
reconstruction, quantitative analysis, as well as qualitative characterization and artistic visualization of BO.
Results: Limited intra-lesional BO representing only 5.8  5.7% of the original debrided cartilage lesion
volume was found in 78 patients with available MRIs at 12 months. The majority (80%) of patients had
very little BO (<10%). Most occurrences of BO carried either spotty (56.4%) or planar (6.4%) morphological
features, and the remaining balance (37.2%) was qualitatively unobservable by eye. Pre-existing BO
recurred at 12 months in the same intra-lesional location in 36% of patients. No statistical correlations
were found between BO and clinical outcomes.
Conclusions: Intra-lesional BO following microfracture-based treatments may not be as severe as pre-
viously believed, its incidence is partly explained by pre-existing conditions, and no relationship to
clinical outcomes exists at 12 months. Morphologically, observable BO was categorized as comprising
either spotty or planar bone.
 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osseus overgrowth in cartilage lesions undergoing repair is
being described in the literature with growing frequency. Unlike
classic osteophyte formation which has been studied extensively
and whose bone alterations are known to be linked to aging,.S. Shive, Piramal Healthcare
Quebec, Canada H7V 4B3.
(M.S. Shive), wstanish@
ternational. Published by Elsevier Ltrauma, mechanical stress, and disease1, intra-lesional bony over-
growth (BO) associated with cartilage repair has never been sys-
tematically studied and its true etiology is unknown.
The lack of cartilage repair studies addressing BO directly
compounded by a shortage of analytical methods has slowed the
development of speciﬁc BO classiﬁcation systems. Most often
limited assessments document the presence of BO or lack thereof,
with an absence of any standardized imaging or morphological
characterization. As a consequence, rates of incidence of BO linked
to cartilage repair have varied widely, ranging from 25 to 70% for
bone marrow stimulation and microfracture in particular2e4, and
from 23 to 64% for autologous chondrocyte implantation4,5. Inter-
estingly, to our knowledge there is still no direct correlationtd. All rights reserved.
Table I
n BO*,y (%) Range
(%, minemax)
(A) Quantiﬁcation of intra-lesional BO at 12 months
All Patients 78z 5.8  5.7k 0.0e25.5
Pain Stiffness Function
(B) Correlationx and 95% Conﬁdence Intervals (CIs) of intra-lesional BO to
WOMAC subscales at 12 months
Pearson’s coefﬁcient
(95% CI)
0.019
(0.194, 0.232)
0.037
(0.174, 0.255)
0.076
(0.165, 0.317)
P-value 0.87 0.75 0.51
* Data represents mean  standard deviation.
y Ratio of bone volume/baseline debrided lesion volume.
z Two patients lost-to-follow-up.
x For correlation analysis BO values were log transformed to ensure a normal
distribution. Pearson’s correlation coefﬁcients were calculated with bootstrap
95% CIs.
k BO for individual microfracture and BST-CarGel groups was 6.4% and 5.4%,
respectively; P ¼ 0.45 by Student’s t-test.
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as pain and function.
Clearly, for a deeper understanding of the etiology and natural
history of intra-lesional BO, the longitudinal use of more sophisti-
cated analytical methods such as quantitative MRI is needed and
should be coupled with the use of validated instruments for patient
reported outcomes. To this end, we took advantage of standardized
MRI scans obtained systematically during a randomized clinical
trial (RCT)6 comparing two microfracture-based surgical treat-
ments in 78 patients and quantiﬁed for the ﬁrst time the exact
amount of intra-lesional BO at 12 months following repair of iso-
lated cartilage lesions in the knee. Our objective was to then
morphologically characterize the intra-lesional BO by using three-
dimensional (3D) reconstructions to classify common features, if
any, and to generate anatomically accurate illustrations, such as
would be observed by naked eye. Finally, the relationship between
the quantiﬁed extent of BO and patient pain, stiffness and function
as measured by the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) was investigated.
Methods
An international, multicenter, RCT of surgical cartilage repair
compared BST-CarGel treatment [Piramal Healthcare (Canada)
Ltd.] to microfracture alone in 80 patients aged 18e55 with full-
thickness cartilage lesions on the femoral condyles6. Unique to
this trial was that standardized 1.5 T MRI scans using customized
high-spatial-resolution pulse sequences were obtained from each
patient pre-treatment, and at 1 and 12 months post-treatment at
pre-qualiﬁed and trainedMRI clinics. For morphological analyses of
cartilage, cartilage lesions and bone, both coronal and sagittal 3D
fat-suppressed spoiled gradient-echo (SPGR), and sagittal 3D
gradient-echo (GRE) sequences were used. Sagittal fat-suppressed
dual echo fast spin-echo sequences were used for T2 relaxation
time analyses. All blinded scans were sent to imaging core labs for
centralized scan quality review and storage (VirtualScopics,
Rochester, NY) and blinded quantitative analysis (Qmetrics Tech-
nologies, Rochester, NY) using validated techniques. Proprietary,
semi-automated (radiologist-corrected) morphological segmenta-
tion utilizing a programmed anatomical atlas for all knee bone and
cartilage structures permitted 3D, quantitative assessments of
cartilage repair. Analyses of 1 month post-treatment scans
measured debrided lesion surface areas and volumes and repre-
sented baseline values. Lesion boundaries on the 1-month scan
provided the reference for 12-month scans, with co-registered
lesion boundaries supervised by a musculoskeletal radiologist
with expertise in cartilage repair. The segmented 3D bone volume at
12 months was used to calculate the percentage of BO as a ratio of
intra-lesional bone volume to the entire debrided lesion volume at 1
month post-treatment in 78/80 patients (two patients were lost-to-
follow-up). Full 3D reconstructions using the complete scans were
then generated of the baseline debrided lesion together with new
intra-lesional bone found at 12 months. Reconstructions were
individually examined and grouped into categories with common
BO morphological features by the musculoskeletal radiologist.
Additionally, pre-treatment and 12-month reconstructions were
compared for each patient to assess recurrence of BO and its loca-
tion. Reconstructions were also used by a medical illustrator (Par-
deux, Longueuil, Quebec) to digitally produce 3D illustrations
representative of each BO category. The WOMAC was administered
to patients pre-treatment and at 3, 6 and 12months post-treatment.
Statistical analyses were conducted using Statistica (v.10, Stat-
Soft, Tulsa, OK) for Student’s t tests. For correlation analyses, SPSS
V22 Statistical software (IBM, New York) was used. BO values were
log transformed to ensure a normal distribution. The Pearson’scorrelation coefﬁcient was calculated with bootstrap 95% conﬁ-
dence intervals (CIs) to evaluate the linear relationship between BO
and the WOMAC measures at 12 months for pain, stiffness and
function subscales. Pearson’s correlation coefﬁcients were obtained
using the variables of percentage of intra-lesional bone and the
WOMAC change from baseline. All reasonable efforts were made to
obtain prior surgical history for all patients, but because most pa-
tients were referred to the 26 sites across Canada, Spain and South
Korea, they came with a lack of, or minimal access to, records and/
or poor patient memory or personal knowledge.
Results
Quantiﬁcation of intra-lesional BO
Quantitative MRI found that the extent of intra-lesional BO was
low with an average of 5.8  5.7% of the original debrided lesion
volumes in all 78 patients with available MRIs at 12 months (6.4%
and 5.4% BO for individual microfracture and BST-CarGel groups,
respectively; P¼ 0.45). See Table I. The frequency distribution of BO
values shown in Fig. 1(A) demonstrates that the majority (80%) of
patients had very little (10% or less) intra-lesional bone volume.
Correlation analysis did not identify a meaningful relationship be-
tween the extent of BO and WOMAC pain, stiffness and function
subscales at 12 months, as seen from the Pearson’s correlation
coefﬁcients shown in Table IB.
3D visualization and categorization
Qualitative examination of 3D reconstructions revealed that
most occurrences of BO carried similar morphological features.
Common features were categorized under either spotty or planar
BO, as shown in Fig. 1(B). Spotty BO was observed as independent
bone protuberances without signiﬁcant height and represented 44/
78 (56.4%) of patients. Planar bone, characterized by plateau-like
structures (sometimes accompanied by spotty bone), was identi-
ﬁed in 6.4% of patients including those with the highest BO per-
centages [14e25%, Fig. 1(A)], but never comprising the entire base
of the lesion as often illustrated in the literature7,8. The BO in 29/78
patients (37.2%) was unobservable, and lacked sufﬁcient volume to
be seen or described in the 3D renderings.
Recurrence of pre-existing bone abnormalities
We found that 28/78 (35.9%) of patients with observable BO at
12 months had pre-existing BO which then re-developed in the
Fig. 1. (A) Frequency distributions for BO. Bars represent the number of patients with BO within a 5% range. The BO is calculated by 3D quantitative MRI using the ratio of intra-
lesional bone volume at 12 months to the baseline (post-debridement) cartilage lesion volume at 1 month post-treatment. More than 80% of patients had less than 10% BO. (B)
Characterization of intra-lesional BO. First row: example of spotty BO; maximum bone height wasw25% of the surrounding cartilage thickness. Second row: example of planar BO;
maximum bone height was w50% of the surrounding cartilage thickness. Third row: example of pre-existing BO recurring at 12 months.
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subchondral bone during the study surgery. An example is shown
in Fig. 1(B). The quantitative volume of 12-month BO was statisti-
cally greater (P ¼ 0.0004) in those patients with pre-existing BO,
than those without.
Discussion
This study demonstrates that the extent of intra-lesional BO
found in 78 patients following microfracture-based cartilage repair
was minimal. In fact, our quantitative analysis found a high fre-
quency (80%) of very low intra-lesional bone volumes (<10%)
which agrees well with our subjective assessment where over 93%
of patients were graded with either spotty or unobservable BO.
Why this study did not yield the excessive level of persistent BO
often associated with microfracture-based therapies9 is unknown.
Most likely this stems from large discrepancies in surgical tech-
nique that exist between surgeons (e.g., debridement) and bone
marrow stimulation procedures (e.g., abrasion, drilling, micro-
fracture), whereas these factors were controlled in this clinical
trial6. However it is also becoming clear that patient history,
particularly previous surgeries and time from onset of symptoms,
impacts post-surgical subchondral bone reactions and remodeling,
and plays a major role in cartilage repair in general8,10e12.
Although it might seem intuitive that intra-lesional BO is a
negative clinical prognostic factor, a full understanding of this issue
has not been reached. First, there is still disagreement regarding
whether remodeling subchondral bone actually undergoes an in-
crease9,13 or a reduction14 in the bone tissue modulus, and what
subsequent effect each has on the overlying articular cartilage. And
while compressive stress likely increases with thinner overlying
cartilage15, no study has directly correlated BO following cartilage
repair to subsequent cartilage degeneration8 or to a decline in
clinical outcomes. Indeed, in our study we were also unable to
identify a statistical correlation between the extent of BO and any of
the WOMAC subscales at 12 months. See Table IB.
We found that 35.9% of patients with BO at 12 months had pre-
existing BO which then re-developed in the identical location after
being resected back to the level of surrounding subchondral bone
during the study surgery. Whether this new BO found at 12 months
was microfracture-related per se cannot be conﬁrmed without a
debridement-only control group. However, this original ﬁnding of
recurrence reiterates the fact that patient history and prior sur-
geries, as well as other joint alterations including joint osteophytes
resulting frommechanical or biochemical stimulation or both1, may
play a principal role in impacting post-operative subchondral bone
reactions8,10e12.
This study is the ﬁrst to speciﬁcally address intra-lesional BO
related to microfracture-based treatments. The primary strength of
this study lies in the availability of longitudinal and standardized
MRIs and novel quantitative methodologies which permitted
comparative assessment of various segmented structures in the
knee, including bone. The ﬁrst-of-its-kind clinical trial conducted
under Good Clinical Practice (GCP) guidelines from which the MRI
data comes was previously described6 and establishes the compa-
rability and reliability of the data. We acknowledge that an obvious
weakness of our ﬁndings is the short 12-month endpoint, but our
on-going 5-year follow-up study may bring deeper insight into
both the dynamic nature of bone overgrowth and its impact on
clinical outcomes. Another weakness is the lack of reliable surgical
histories for all patients which may have allowed an assessment of
impact, if any, that prior cartilage repair surgery might have on
recurrence of BO. In a more general sense, our analysis certainly
suffers from the fact that there is no precedent for assessing intra-
lesional BO, and certainly no recognized and validated scoringmethod, so that the data contained herein stands alone and cannot
be compared to or standardized with, other studies. The challenge
of comparing anecdotal literature or subjective two-dimensional
radiology to novel 3D quantitative analyses is problematic: how do
we compare our measured BO with such low quantitative magni-
tude but such high incidence (77/78 patients or 99%) to other re-
ports2,3,5 where BO scoring was limited to incidence (i.e., present or
not) or lacked an assessment of magnitude9? Such questions
highlight the underlying rationale for this communication which is
to expand current knowledge of BO following cartilage repair, and
to suggest that more emphasis needs to be put on quantitative
reporting and the clinical relevance of BO.
Conclusion
Current orthopedic understanding of cartilage repair-associated
intra-lesional BO is limited due to a lack of standardized longitu-
dinal studies directed at understanding its etiology and clinical
signiﬁcance. Our quantiﬁcation of bone volume with sophisticated
imagingmethods coupled with 3D visualization represents the ﬁrst
systematic assessment of intra-lesional BO in the context of a
multicenter RCT comparing two microfracture-based therapies.
However, contrary to present dogma, we have demonstrated for the
ﬁrst time that while BO does occur following microfracture-based
therapies, it is to a minimal extent quantitatively and its inci-
dence is partly explained by pre-existing conditions. Morphologi-
cally, observable BO was categorized as comprising either spotty or
planar bone. Finally, we could not identify a correlation between
the extent of BO and clinical outcomes at 12 months.
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